6.
Wang H, Zhu Y, Cui Q, Wu W, Li G, Chen D
. Epidemiology and Antimicrobial Resistance Profiles of the Species in China, 2009 to 2021. Microbiol Spectr. 2022; 10(2):e0156021.
PMC: 9045199.
DOI: 10.1128/spectrum.01560-21.
View
7.
Margalit I, Lebeaux D, Tishler O, Goldberg E, Bishara J, Yahav D
. How do I manage nocardiosis?. Clin Microbiol Infect. 2021; 27(4):550-558.
DOI: 10.1016/j.cmi.2020.12.019.
View
8.
An H, Sun W, Liu X, Wang T, Qiao J, Liang J
. activities of contezolid (MRX-I) against drug-sensitive and drug-resistant . Microbiol Spectr. 2023; :e0462722.
PMC: 10580816.
DOI: 10.1128/spectrum.04627-22.
View
9.
Goldstein E, Citron D, Merriam C, Warren Y, Tyrrell K, Fernandez H
. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. Antimicrob Agents Chemother. 2004; 48(6):2149-52.
PMC: 415607.
DOI: 10.1128/AAC.48.6.2149-2152.2004.
View
10.
Adjemian J, Frankland T, Daida Y, Honda J, Olivier K, Zelazny A
. Epidemiology of Nontuberculous Mycobacterial Lung Disease and Tuberculosis, Hawaii, USA. Emerg Infect Dis. 2017; 23(3):439-447.
PMC: 5382761.
DOI: 10.3201/eid2303.161827.
View
11.
Barberis C, Sandoval E, Rodriguez C, Ramirez M, Famiglietti A, Almuzara M
. Comparison between disk diffusion and agar dilution methods to determine in vitro susceptibility of Corynebacterium spp. clinical isolates and update of their susceptibility. J Glob Antimicrob Resist. 2018; 14:246-252.
DOI: 10.1016/j.jgar.2018.05.009.
View
12.
Ruth M, Koeken V, Pennings L, Svensson E, Wertheim H, Hoefsloot W
. Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?. J Antimicrob Chemother. 2019; 75(3):609-617.
PMC: 7021090.
DOI: 10.1093/jac/dkz511.
View
13.
Hamdi A, Fida M, Deml S, Abu Saleh O, Wengenack N
. Retrospective Analysis of Antimicrobial Susceptibility Profiles of Species from a Tertiary Hospital and Reference Laboratory, 2011 to 2017. Antimicrob Agents Chemother. 2019; 64(3).
PMC: 7038297.
DOI: 10.1128/AAC.01868-19.
View
14.
Kim D, Kim S, Koh W, Jhun B
. Activity of Oxazolidinone against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates. Antimicrob Agents Chemother. 2021; 65(7):e0230620.
PMC: 8218642.
DOI: 10.1128/AAC.02306-20.
View
15.
Liu C, Song Y, He W, Liu D, He P, Bao J
. Nontuberculous mycobacteria in China: incidence and antimicrobial resistance spectrum from a nationwide survey. Infect Dis Poverty. 2021; 10(1):59.
PMC: 8082609.
DOI: 10.1186/s40249-021-00844-1.
View
16.
Hu L, Huang X, Yee N, Meng H, Jiang L, Liang L
. an emerging pathogen that is easily misdiagnosed and given treatment as a fungus. Front Cell Infect Microbiol. 2024; 14:1430032.
PMC: 11390559.
DOI: 10.3389/fcimb.2024.1430032.
View
17.
Goldstein E, Citron D, Merriam C
. Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans. Antimicrob Agents Chemother. 1999; 43(6):1469-74.
PMC: 89299.
DOI: 10.1128/AAC.43.6.1469.
View
18.
Zong Z, Jing W, Shi J, Wen S, Zhang T, Huo F
. Comparison of Activity and MIC Distributions between the Novel Oxazolidinone Delpazolid and Linezolid against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis in China. Antimicrob Agents Chemother. 2018; 62(8).
PMC: 6105784.
DOI: 10.1128/AAC.00165-18.
View
19.
Brown-Elliott B, Rubio A, Wallace Jr R
. Susceptibility Testing of a Novel Benzimidazole, SPR719, against Nontuberculous Mycobacteria. Antimicrob Agents Chemother. 2018; 62(11).
PMC: 6201134.
DOI: 10.1128/AAC.01503-18.
View
20.
Aono A, Murase Y, Chikamatsu K, Igarashi Y, Shimomura Y, Hosoya M
. In vitro activity of tedizolid and linezolid against multidrug-resistant Mycobacterium tuberculosis: a comparative study using microdilution broth assay and genomics. Diagn Microbiol Infect Dis. 2022; 103(3):115714.
DOI: 10.1016/j.diagmicrobio.2022.115714.
View